Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU

Inclusion Criteria: * Pediatric patient (1 month-18 years old) * Affected by STEC-HUS defined by : * Thrombocytopenia (\<150 000/mm3) * Mechanic hemolytic anemia (Hemoglobin \< 10g/dL, haptoglobin \<LLN, lactate dehydrogenase (LDH) \>upper limit of normal (ULN) and/or bilirubin \> ULN, presence of schizocytes) * ARF defined by an estimated Schwartz 2009 creatinin clearance \<75ml/min/1,73m² * With prodromal diarrhea and/or presence of an enterohemorrhagic strain of Escherichia Coli and/or identification of the Stx 1 or 2 genes in the stool sample or rectal swab * Written consent of the 2 parents * Female patients of childbearing potential must be practicing an effective, reliable and medically acceptable contraceptive regimen during the entire duration of the study and 5 months after the end of the participation. Exclusion Criteria: * Neonatal HUS * Malignancy * Known HIV infection * Pregnancy or lactation * Identified drug exposure-related HUS * Infection-related HUS * Known systemic lupus erythematosus or antiphospholipid antibody positivity or syndrome * Patient already enrolled in a drug trial * Patient with ongoing meningococcal infection * Patient affected by aHUS or family history of aHUS * STEC-HUS patient with severe multiorgan involvement at diagnostic: * Neurological involvement (seizures, coma, focal deficit) with signs of microangiopathy on cerebral Magnetic Resonance Imaging. * Cardiac involvement (cardiac failure, ischemic myocarditis, conduction or rhy…